Press Releases*

All Releases
View Summary Genomic Health Presents Results Furthering Understanding of Biology of Prostate Cancer at the 2012 Genitourinary Cancers Symposium
Feb 3, 2012 		PDF 13.0 KB
View Summary Genomic Health to Announce Fourth Quarter and Year-End 2011 Financial Results and Host Conference Call on Monday, February 6, 2012
Jan 30, 2012 		PDF 14.2 KB
View Summary Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
Jan 20, 2012 		PDF 15.3 KB
View Summary Genomic Health Announces Initiation of Clinical Validation Study of Prostate Cancer Test; Acceleration of Next Generation Sequencing Program
Jan 9, 2012 		PDF 14.8 KB
View Summary Genomic Health to Present at the J.P. Morgan Healthcare Conference
Jan 3, 2012 		PDF 11.5 KB
View Summary Genomic Health Announces Results from Fourteen Studies Emphasizing Belief of Physicians around the World in the Value of Oncotype DX
Dec 12, 2011 		PDF 18.6 KB
View Summary Genomic Health Announces Positive Results of First Clinical Outcomes Study for Biomarker Discovery Using Next Generation Sequencing at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Dec 8, 2011 		PDF 15.2 KB
View Summary Genomic Health Announces Positive Study Results Validating Use of Oncotype DX® in DCIS Breast Cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Dec 6, 2011 		PDF 15.9 KB
View Summary Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Nov 29, 2011 		PDF 22.5 KB
View Summary Genomic Health to Present at the Piper Jaffray Health Care Conference
Nov 22, 2011 		PDF 11.1 KB
View Summary Genomic Health Announces Publication of QUASAR Study Confirming Oncotype DX® Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients
Nov 8, 2011 		PDF 14.8 KB
View Summary Genomic Health Announces Third Quarter 2011 Financial Results and Business Progress
Nov 1, 2011 		PDF 22.5 KB
View Summary Genomic Health to Announce Third Quarter 2011 Financial Results and Host Conference Call on Tuesday, November 1, 2011
Oct 25, 2011 		PDF 10.8 KB
View Summary Genomic Health Launches Smartphone Application to Improve Access to Important Treatment Information for Newly Diagnosed Breast and Colon Cancer Patients
Oct 25, 2011 		PDF 17.7 KB
View Summary Genomic Health Announces Medicare Coverage for Oncotype DX® Colon Cancer Test
Sep 30, 2011 		PDF 15.1 KB
View Summary Genomic Health to Present at the JMP Securities Healthcare Conference
Sep 21, 2011 		PDF 10.4 KB
View Summary Genomic Health Announces Presentation of Five Studies in Breast and Colon Cancers at the 2011 European Multidisciplinary Cancer Congress
Sep 13, 2011 		PDF 17.7 KB
View Summary Genomic Health to Present at the Canaccord Genuity Growth Conference
Aug 4, 2011 		PDF 9.6 KB
View Summary Genomic Health Announces Second Quarter 2011 Financial Results and Business Progress
Aug 3, 2011 		PDF 21.6 KB
View Summary Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011
Jul 27, 2011 		PDF 9.7 KB
Showing 1-20 of 208 Page: 1 2 3 ... 11  Next 20

*ASCO® is a registered trademark of the American Society of Clinical Oncology. ASCO does not endorse any product or therapy. NCCN® is a registered trademark of the National Comprehensive Cancer Network. The NCCN does not endorse any product or therapy.

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

 

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

 

Shareholder Tools

  

DISCLAIMER

The information in the press releases should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.


Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.